We have observed
15 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after March 15, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS
CALCIUM SEQUESTERING COMPOSITION
HIGH EXPRESSION CEREAL PHYTASE GENE
Classification of cancers
DONEPEZIL PAMOATE, PREPARATION METHOD AND ITS USE
MANDELIC ACID CONDENSATION POLYMERS
COMPOSITION AND METHOD FOR TREATING NUCLEIC ACID-RELATED EYE DISEASE
ARYL NAPHTHALIDE LIGNANS AS ANTI-HIV AGENTS
ISOLATION OF SELECTED MARKER-FREE MICROORGANISMS WITH A KNOWN GENETIC ELEMENT
MICROANALYSIS OF CELLULAR FUNCTION
RAPID SCREENING OF MONOCLONAL ANTIBODIES
CORROSION INHIBITING COMPOSITION
Production of biodiesel by yeast from lignocellulose and glycerol
METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT